Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012

Christopher N. Kaufmann, Adam P. Spira, Colin A. Depp, Ramin Mojtabai

Research output: Contribution to journalReview articlepeer-review

Abstract

Objectives.To assess trends in continuing and new prescriptions for sedative-hypnotic medications, including benzodiazepines (BZDs) and non-BZD receptor agonists (nBZRAs). Methods. Data came from the National Ambulatory Medical Care Survey and comprised 287 288 randomly sampled patient visits. Physicians reported medications prescribed and whether they were "continuing" or "new" prescriptions. We assessed trends in continuing BZD, new BZD, continuing nBZRA, and new nBZRA prescriptions from 2005 to 2012. Results. Proportions of visits with continuing prescriptions increased from 3.4% in 2005 to 4.7% in 2012 (P < .01) for BZDs, and from 1.0% to 1.7% (P < .01) for nBZRAs. We noted no changes in new prescriptions. We observed the same patterns across patient age and physician specialties, except psychiatry. Despite no growth over time, the prevalence of visits involving continuing and new BZD and nBZRA prescriptions was much higher in psychiatry than in primary care and other specialties. Conclusions. Increased sedative-hypnotic prescribing in recent years may be attributable to long-Term growth in continuing prescriptions, rather than new prescriptions. Public Health Implications. Findings call for renewed efforts to limit continuing prescribing of sedative-hypnotics to reduce their use in the population.

Original languageEnglish (US)
Pages (from-to)2019-2025
Number of pages7
JournalAmerican journal of public health
Volume106
Issue number11
DOIs
StatePublished - Nov 2016

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Continuing versus new prescriptions for sedative-hypnotic medications: United States, 2005-2012'. Together they form a unique fingerprint.

Cite this